Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL

An Open Label, 1-sequence Cross-over, Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Receptor Occupancy of Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUEL XR®) in Healthy Male Volunteers

The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.

Inclusion Criteria:

• Normal MRI scan
• Body mass index 19-30 kg/m2 and weight of 50-100 kg
• Clinically normal physical findings, medical history and laboratory values

Exclusion Criteria:

• Trauma or sickness last 2 weeks before the first PET examination.
• A history or presence of neurological, haematological, psychiatric, gastrointestinal, hepatic, pulmonary, renal disease or other condition as judged by the Investigator
• Any previous participation in a PET study
• Subjects suffer from claustrophobia